Crossref
487P Real-world outcomes to frontline standard of care gemcitabine/cisplatin plus durvalumab in IDH1 mutated advanced cholangiocarcinoma in the US
Annals of Oncology · 2026-12 · 37 · S554
DOI: 10.1016/j.annonc.2026.08.577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von A. Lamarca und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Lamarca, A., Kim, R., Azzi, J. A., Sofeu, C., Yi, D., & Lee, S. (2026). 487P Real-world outcomes to frontline standard of care gemcitabine/cisplatin plus durvalumab in IDH1 mutated advanced cholangiocarcinoma in the US. Annals of Oncology, 37, S554. https://doi.org/10.1016/j.annonc.2026.08.577
Vancouver
Lamarca A, Kim R, Azzi JA, Sofeu C, Yi D, Lee S. 487P Real-world outcomes to frontline standard of care gemcitabine/cisplatin plus durvalumab in IDH1 mutated advanced cholangiocarcinoma in the US. Annals of Oncology. 2026;37:S554. doi:10.1016/j.annonc.2026.08.577
BibTeX
@article{Lamarca2026,
author = {Lamarca, A. and Kim, R.D. and Azzi, J. Al and Sofeu, C. and Yi, D. and Lee, S.},
title = {487P Real-world outcomes to frontline standard of care gemcitabine/cisplatin plus durvalumab in IDH1 mutated advanced cholangiocarcinoma in the US},
journal = {Annals of Oncology},
year = {2026},
volume = {37},
pages = {S554},
doi = {10.1016/j.annonc.2026.08.577}
}
EUVIMED